Skip to main content
. 2021 Aug 3;2(2):115–126. doi: 10.1016/j.bpsgos.2021.07.008

Table 1.

Cohorts of Individuals Diagnosed With Major Depressive Disorder and Assessed for Depressive Symptoms Before and After Treatment With Antidepressant Medication

Study (Reference) Country, Region Study Design Study Length, Weeks Medication(s) Measure Median Age, Years IQR for Age, Years Female Na npercentage improvement nremit nnonremit
European Ancestry
STAR∗D (52) United States Open label 12 Citalopram QIDSC 44 32–53 58% 1163 1163 506 657
GSRD (17) Europe Naturalistic >4 Various MADRS 52.5 43–61 66% 1152 1152 189 963
GENDEP (53) Europe Partially randomized RCT 12 Escitalopram, nortriptyline MADRS 43 33–51 63% 783 783 291 365
DAST (see Supplement 1) Germany Naturalistic inpatient 6 Various HAMD-21 50 37–62 57% 586 586 245 303
PGRN-AMPS (54) United States Open label 8 Citalopram, escitalopram QIDSC 38.5 28–49 63% 490 392 200 290
GENPOD (18) United Kingdom Open label 12 Citalopram, reboxetine BDI 38 30–48 69% 474 474 169 305
PFZ (18) United States RCT 6-8 Sertraline, fluoxetine, paroxetine HAMD-17 43 32–54 67% 309 309 99 210
Mayo (16) United States Open label 8 Citalopram, escitalopram HAMD-17 37 29–51 62% 156 156 80 76
GSK (18) United States RCT 8 Escitalopram HAMD-17 36 25.75–45 55% 132 132 56 76
GODS (18) Switzerland Open label 8 Paroxetine MADRS 37 29.5–43.5 52% 71 71 17 54
East Asian Ancestry
Miaoli (16) Taiwan Open label 8 Escitalopram, paroxetine HAMD-17 41 30–52 82% 233 233 103 130
Taipei (16) Taiwan Open label 8 Fluoxetine, citalopram HAMD-17 46 34–59 55% 174 174 45 129
Japan (16) Japan RCT 6 Fluvoxamine, paroxetine HAMD-17 44.5 32–56 47% 120 120 78 42
Total 5843 5745 2078 3600

BDI, Beck Depression Inventory; DAST, Depression and Sequence of Treatment; GENDEP, Genome Based Therapeutic Drugs for Depression; GENPOD, GENetic and clinical Predictors Of treatment response in Depression; GODS, Geneva Outpatient Depression Study; GSK, Glaxo Smith Kline; GSRD, Group for the Study of Resistant Depression; HAMD-17, 17-item Hamilton Depression Rating Scale; HAMD-21, 21-item Hamilton Depression Rating Scale; IQR, interquartile range; MADRS, Montgomery–Åsberg Depression Rating Scale; PFZ, Pfizer; PGRN-AMPS, Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study; QIDSC, Quick Inventory of Depressive Symptomatology; RCT, randomized controlled trial; STAR∗D, Sequenced Treatment Alternatives to Relieve Depression.

a

Number of participants included after quality control of genetic and clinical data.